Conditions: Mevalonate Kinase Deficiency
Keywords: Hyper IgD syndrome canakinumab HIDS mevalonate kinase deficiency MKD
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 9
Healthy volunteers: no

Brief summary:
This pilot study is designed to evaluate the efficacy, the safety, and the pharmacokinetics (PK) / pharmacodynamics (PD) of canakinumab treatment in patients with HIDS.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Canakinumab
Intervention descriptions: intervention 1: None

Protocol document: